Your browser doesn't support javascript.
loading
Determination of Pathogenicity of Breast Cancer 1 Gene Variants using the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines.
Brown, Angela; Zamanpoor, Mansour; Love, Donald R; Prosser, Debra O.
Afiliación
  • Brown A; Wellington Regional Genetics Laboratory, Wellington Hospital, Wellington, New Zealand.
  • Zamanpoor M; Wellington Regional Genetics Laboratory, Wellington Hospital, Wellington, New Zealand.
  • Love DR; Diagnostic Genetics, LabPLUS, Auckland City Hospital, Auckland, New Zealand.
  • Prosser DO; Department of Pathology, Sidra Medicine, Doha, Qatar.
Sultan Qaboos Univ Med J ; 19(4): e324-e334, 2019 Nov.
Article en En | MEDLINE | ID: mdl-31897316
ABSTRACT

OBJECTIVES:

Molecular diagnostic laboratories screen for mutations in disease-causing genes in order to confirm a clinical diagnosis. The classification of DNA variants as 'pathogenic' or 'likely pathogenic' mutations creates a workflow bottleneck, which becomes increasingly challenging as greater number of genes are screened. The classification challenge is also acute if there are conflicting reports regarding pathogenicity and differing classification criteria between laboratories. This study aimed to compare two procedures for the classification of variants in the breast cancer (BRCA)1 gene.

METHODS:

This bioinformatic study was conducted at LabPLUS, Auckland, New Zealand, from February to June 2017. DNA was extracted from peripheral blood samples of 30 patients and gene library construction was carried out using a commercially available targeted panel for the BRCA1 and BRCA2 genes. The genes were subsequently sequenced and the sequence data analysed. The guidelines published by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) provides a comprehensive framework for the interpretation of variants in genes that are associated with Mendelian disorders. The use of these guidelines were compared to the variant classifications that were achieved by reference to those reported in the BRCA Exchange database.

RESULTS:

The results showed concordance between the two classification protocols for a panel of 30 BRCA1 gene variants, although the transparency in following the ACMG/AMP guidelines provides a diagnostic laboratory with a generalisable approach that allows laboratory-directed revisions to be undertaken in light of new information.

CONCLUSION:

The ACMG/AMP-based guidelines were applied to a cohort of patients with BRCA1 gene variants. The use of these guidelines provides a system which creates consistency in variant interpretation and supports subsequent clinical management.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Variación Genética / Neoplasias de la Mama / Pruebas Genéticas / Guías de Práctica Clínica como Asunto / Genes BRCA1 / Genes BRCA2 Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Female / Humans País/Región como asunto: Oceania Idioma: En Revista: Sultan Qaboos Univ Med J Año: 2019 Tipo del documento: Article País de afiliación: Nueva Zelanda

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Variación Genética / Neoplasias de la Mama / Pruebas Genéticas / Guías de Práctica Clínica como Asunto / Genes BRCA1 / Genes BRCA2 Tipo de estudio: Guideline / Prognostic_studies / Risk_factors_studies Límite: Female / Humans País/Región como asunto: Oceania Idioma: En Revista: Sultan Qaboos Univ Med J Año: 2019 Tipo del documento: Article País de afiliación: Nueva Zelanda